Macfarlane D - Search Results

1

Reducing Amputations in People with Diabetes (RAPID): Evaluation of a New Care Pathway.

MacRury S, Stephen K, Main F, Gorman J, Jones S, Macfarlane D. MacRury S, et al. Among authors: macfarlane d. Int J Environ Res Public Health. 2018 May 16;15(5):999. doi: 10.3390/ijerph15050999. Int J Environ Res Public Health. 2018. PMID: 29772673 Free PMC article.

2

Technology-enabled remote management of diabetes foot disease and potential for reduction in associated health costs: a pilot study.

Main F, Zubala A, Gorman J, Jones S, Hall J, Macfarlane D, MacRury S. Main F, et al. Among authors: macfarlane d. J Foot Ankle Res. 2021 Jan 13;14(1):7. doi: 10.1186/s13047-020-00444-6. J Foot Ankle Res. 2021. PMID: 33436028 Free PMC article.

3

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.

4

Oral antidiabetic agents as cardiovascular drugs.

Macfarlane DP, Paterson KR, Fisher M. Macfarlane DP, et al. Diabetes Obes Metab. 2007 Jan;9(1):23-30. doi: 10.1111/j.1463-1326.2006.00592.x. Diabetes Obes Metab. 2007. PMID: 17199715 Review.

5

The impact of glucose exposure on bioenergetics and function in a cultured endothelial cell model and the implications for cardiovascular health in diabetes.

Fiorello ML, Treweeke AT, Macfarlane DP, Megson IL. Fiorello ML, et al. Sci Rep. 2020 Nov 11;10(1):19547. doi: 10.1038/s41598-020-76505-4. Sci Rep. 2020. PMID: 33177612 Free PMC article.

6

Subclinical and asymptomatic parathyroid disease: implications of emerging data.

Macfarlane DP, Yu N, Leese GP. Macfarlane DP, et al. Lancet Diabetes Endocrinol. 2013 Dec;1(4):329-40. doi: 10.1016/S2213-8587(13)70083-4. Epub 2013 Oct 24. Lancet Diabetes Endocrinol. 2013. PMID: 24622418 Review.

7

Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.

Macfarlane DP, Paterson KR, Fisher M. Macfarlane DP, et al. Diabetes Obes Metab. 2008 Jul;10(7):533-44. doi: 10.1111/j.1463-1326.2007.00735.x. Epub 2008 Feb 1. Diabetes Obes Metab. 2008. PMID: 18248492 Review.

8

Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data.

Macfarlane DP, Fisher M. Macfarlane DP, et al. Am J Cardiovasc Drugs. 2006;6(5):297-304. doi: 10.2165/00129784-200606050-00002. Am J Cardiovasc Drugs. 2006. PMID: 17083264 Review.

9

Intermittent exposure of cultured endothelial cells to physiologically relevant fructose concentrations has a profound impact on nitric oxide production and bioenergetics.

Fiorello ML, Treweeke AT, Macfarlane DP, Megson IL. Fiorello ML, et al. PLoS One. 2022 May 13;17(5):e0267675. doi: 10.1371/journal.pone.0267675. eCollection 2022. PLoS One. 2022. PMID: 35560114 Free PMC article.

10

Asymptomatic and mild primary hyperparathyroidism.

Macfarlane DP, Yu N, Leese GP. Macfarlane DP, et al. Ann Endocrinol (Paris). 2015 May;76(2):120-7. doi: 10.1016/j.ando.2015.03.001. Epub 2015 Apr 14. Ann Endocrinol (Paris). 2015. PMID: 25882891 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

964 results

Search Page